The Cholesterol-Lowering Drugs Market Will Reach $24.63bn In 2019 Predicts New Visiongain Report

14 September 2018
Pharma

A new report by visiongain predicts that the global cholesterol-lowering drugs market will reach $24.63bn in 2019. This forecast and others appear in Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists, published in October 2015. Visiongain is a business information provider based in London, UK.

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists report examines the current and future trends in the cholesterol-lowering drugs market. High cholesterol levels are present in a large percentage of the world’s population, leading to an increasing level of cardiovascular diseases. The important of managing cholesterol levels has become increasingly important to healthcare professionals in recent years, and the demand for more effective treatments has grown accordingly. A raft of new, more efficacious therapies is entering the market and these are forecast to lift revenues for the sector, with these medicines able to treat patients who have resisted current treatments.

In this report, we examine in detail a number of key national markets, as well as the sales of a wide range of leading cholesterol-lowering drugs in the following submarkets: statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs. Forecasts are also provided for leading products in each submarket. Using our experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national markets and treatment areas, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the cholesterol-lowering drugs market. This includes a look at their current products, as well those presently in development. Recent financial performance is analysed, along with a breakdown of each company’s leading products and an analysis of news that may influence the course of the company.

Jack Evans, a pharmaceutical and medical devices industry analyst in visiongain, said: “The long-awaited market launch of PCSK9 inhibitors in 2015 could lead to a revolution in the treatment of patients with hypercholesterolaemia, even if these drugs are reserved for a select subgroup of patients.”
Visiongain’s report provides revenue forecasts to 2025 for the cholesterol-lowering drugs market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, Abbvie, Novartis, Sanofi and Amgen.

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever